Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cyxone in strategic development co-operation with European CRO

Cyxone can announce today that it has established a long-term strategic co-operation agreement with Sourcia, a clinical contract research organization (CRO) with offices in Belgium, Germany, and the Netherlands.Cyxone's business model is to establish co-operation with different partners, and limited numbers of its own staff, to conduct studies flexibly and cost effectively. We have previously reported on our studies with T20K carried out by companies in Australia, Austria, Denmark, Germany, Sweden, Switzerland, and the US. To efficiently take T20K through the pre-clinical studies and

Less food waste reduces climate change

Food & beverage is one of Coor’s largest service areas, and Coor’s 120 restaurants makes it one of the Nordics’ leading restaurant operators. In order to reduce food waste, Coor will start to measure all food waste. The objective is to reduce food waste by a total of 20 per cent in one year.Food waste currently causes a large proportion of the overall environmental impact in the Nordics and needs to be reduced throughout the food supply chain—by manufacturers, wholesalers, suppliers, stores, restaurants, catering kitchens and households. Coor is one of the Nordics’ leading FM providers, and

Veho and Caverion reduced carbon dioxide emissions in real estate by 830 tonnes

Caverion Corporation Press release 18 May, 2017 at 10.00 a.m. EESTVeho and Caverion reduced carbon dioxide emissions in real estate by 830 tonnes Caverion and Veho have achieved significant results in improving Veho's real estates’ energy efficiency. In 2016, the total energy savings achieved by energy efficiency improvement, real estate utilisation optimisation, 24/7 real estate control, and energy management were around 3,750 MWh, which means a reduction in carbon dioxide emissions by about 830 tonnes. “The emissions saved are equivalent to driving approximately 8.3 million

VTT's autonomous cars take to public roads and start communicating with each other

Marilyn, the first automated car to be granted a road traffic testing permit in Finland, and its spouse Martti have taken things to a new level together and started exchanging information with each other and their driving environment. They will take the next step in their relationship in the autumn, when the public digital infrastructure can also talk with the couple.   The automated cars developed by VTT Technical Research Centre of Finland can hear, see and sense, and Finnish intelligence hums in their brains. They are able to follow a pre-programmed route and avoid collisions with

Elocta® approved in the Kingdom of Saudi Arabia for the treatment of haemophilia A

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces that the Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia has approved Elocta® (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein with an extended half-life, for the treatment of haemophilia A.  Elocta is the first extended half-life and recombinant factor VIII Fc fusion protein therapy approved for the treatment of haemophilia A in Saudi Arabia.  “The approval of Elocta in Saudi Arabia is an important development for the haemophilia community in the Middle East and will

SSAB entering new North African markets

SSAB has recently opened an office in Egypt and is working on establishing one in Algeria. Both countries offer great potential for new business opportunities, and the start in Egypt has been very good. There are also plans related to Western and Central Africa. Regional sales managers Mostafa Hussein and Carl Robert Borgenstierna meeting customers in Egypt. Watch the interview of Carl Robert Borgenstierna in YouTube . SSAB aims for global leadership in Quenched & Tempered Steels (Q&T) and in targeted Advanced High-Strength Steels (AHSS)

Ratos AB: Notice to attend the Extraordinary General Meeting of Ratos AB (publ.)

Press release 18 May 2017  Shareholders of Ratos AB (publ), reg.nr 556008-3585, are hereby invited to the Extraordinary General Meeting on Wednesday, 14 June 2017 at 11.00 CET at Sibeliussalen, Finlandshusets konferens, Snickarbacken 4, Stockholm. Registration to the Meeting, starts at 10.30 CET. NotificationShareholders who wish to attend the Meeting must firstly be recorded in the register of shareholders maintained by Euroclear Sweden AB on Thursday, 8 June 2017,secondly give notice of attendance to the company no later than Thursday, 8 June, 2017. Notice of attendance

NeuroVive Pharmaceutical AB Interim report January - March 2017

Broadened project portfolioBusiness operations Significant events January-March 2017 • Strong inhibitory effects demonstrated in human hepatocellular carcinoma cells and in an experimental model of liver cancer with the Company’s new generation of sanglifehrin-based compounds in the NVP024 project. • The business operations of the Taiwanese subsidiary were sold to the Taiwanese shareholders in order to reallocate research resources to the Parent Company. • Collaboration agreement signed with a prestigious US research team in mitochondrial medicine for the NVP015 project focused

Addnode Group acquires software company Canella and strengthens its position in welfare and pharmacy solutions

Stockholm, May 18, 2017. Addnode Group has acquired the Swedish software company Canella, which develops solutions for the Nordic pharmacy and welfare market. The company had net sales of SEK 19 M in 2016.Canella delivers solutions based on the proprietary software Candos to pharmacists and county councils. Candos is approved by the Swedish eHealth Agency and is well integrated with systems used in pharmacy and healthcare. "I see very nice development opportunities with the acquisition of Canella. We acquire unique pharmaceutical skills and a modern software that will strengthen our

Interim report for the first quarter 2017: Strong start to the year creates good conditions for the future

Interim report for the period 1 January – 31 March 2017All amounts in the report relate to the Group and are stated in SEK thousands unless otherwise indicated. Figures in brackets refer to the corresponding period in the previous year.  First quarter · Revenue amounted to SEK 40,964 (4,048) thousand, an increase of 912%. · Operating profit before depreciation (EBITDA) was SEK 25,042 (-584) thousand. · Operating profit (EBIT) was SEK 24,797 (-721) thousand. Significant events after the first quarter · SEK 8,999,995.50 of the convertible debenture has been converted

IES Nomination Committee ahead of Annual General Meeting 2017

The Nomination Committee of Internationella Engelska Skolan i Sverige Holdings II AB (“Internationella Engelska Skolan” or “IES”) consists of representatives of the three main shareholders included in the company’s shareholder register as of 30 April 2017. The main purpose and responsibility of the Nomination Committee is to present proposals for the election and remuneration of the Chairman and the Board of Directors as well as the Auditors to the Annual General Meeting 2017. On 30 April 2017, the three largest shareholders of Internationella Engelska Skolan were IES Holdings I (71.2%

A quarter of growth and consolidation

First quarter: January-March 2017 · Operating revenue amounted to SEK 1,649 M (1,471), an increase of 12% or SEK 178 M. · Operating profit was SEK 66 M (41 incl. SEK -38 M in IPO costs).   · Net profit after tax for the period was SEK 40 M (-16). · Earnings per share for the period before and after dilution were SEK 0.76 (-0.82). · Operating cash flow was SEK -16 M (29). Events during the first quarter and after the end of the period · There are no significant events to report for the first quarter or after the end of the quarter.  Presentation of report today at

Internationella Engelska Skolan - Interim Report (1 July - 31 March 2016/2017)

Progress of operations in quarter 3 (January-March) · Total operating income was up by 12.5% on the corresponding quarter of the previous year, mainly due to increased student numbers, and central government subsidies for “Lärarlönelyftet”, and amounted to MSEK 541.4 (481.5) · The number of students in the Swedish operation at the end of the quarter was 21 420 (19 795) · There were around 144,000 registrations on waiting lists at the end of the quarter, an increase of some 17,000 registrations, (13%) compared to the corresponding period in the previous year · Operating profit (

Qliro Group issues bond

Qliro Group AB (publ) “Qliro Group” has issued a three-year senior unsecured bond in the amount of SEK 250 million. The issue proceeds will be used to accelerate the development in Qliro Financial Services and other general corporate purposes.Qliro Group has issued a senior unsecured bond of SEK 250 million with a floating rate coupon of 3 month Stibor + 4.80 percent and a final maturity in May 2020. The total framework amounts to SEK 500 million and the company may look to tap the remaining bonds at a later stage. Qliro Group intends to apply for listing of the bond on Nasdaq Stockholm

Proposal of remedies to meet requirements of the EU Merger Regulation

On April 12, 2017 Nordic Capital Fund VIII, currently the indirect majority shareholder in Lindorff, notified the European Commission of the intended combination of Intrum Justitia and Lindorff. Based on its initial investigation, the European Commission has informed the parties of potential competition concerns in five Nordic/Baltic markets, relating to both debt collection and debt purchasing in each market. The parties have therefore proposed a divestment of Lindorff’s entire business in Denmark, Estonia, Finland and Sweden as well as Intrum Justitia’s entire business in Norway. In

Oncopeptides AB Interim Report January - March 2017

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the first quarter 2017 report. ”Our IPO received strong interest both from Sweden and internationally, including several well-renowned institutional long term investors. We are now fully financed to drive our broad clinical development program in late-stage multiple myeloma patients, including a phase II trial to be initiated and the ongoing phase II trials and the pivotal phase III trial OCEAN.”SUMMARY OF Q 1  January 1st – March 31st 2017 · Net sales amounted to 0.0 (0.0) MSEK · Loss for the period

Viking Line: Interim Management Statement for the period January - March 2017

Viking Line Abp            BUSINESS REVIEW         18.5.2017, 9.00 AMINTERIM MANAGEMENT STATEMENT FOR THE PERIOD JANUARY–MARCH 2017Consolidated sales of the Viking Line Group for the period January 1–March 31, 2017 were 102.1 million euros (EUR 106.9 M for January 1–March 31, 2016). Other operating revenue amounted to EUR 0.1 M (1.5). Operating income totalled EUR -17.7 M (-11.6). Net financial items totalled EUR -1.1 M (-1.5). Consolidated income before taxes amounted to EUR -18.8 M (-13.1). Income after taxes totalled EUR -15.1 M (-10.5).Competition in Viking Line’s service area

H+H International A/S - Interim financial report Q1 2017

Company Announcement No. 248, 2017 Copenhagen, Denmark, 2017-05-18 08:00 CEST (GLOBE NEWSWIRE) --   H+H International A/SDampfærgevej 3, 3rd Floor2100 Copenhagen ØDenmarkTel.: +45 35 27 02 00www.HplusH.comCompany reg. no. 49 61 98 12LEI 213800GJODT6FV8QM841         Highlights for the period 1 January to 31 March 2017 · Revenue for the first quarter of 2017 increased by 6% in local currencies (organic growth) and increased by 2% in DKK to DKK 376.5 million (2016: DKK 367.9 million). · EBITDA before special items for the first quarter of 2017 was DKK

Hexagon Composites supports Indonesia's CNG conversion ramp-up

Hexagon Composites' subsidiary Hexagon Raufoss has recently received orders from PT Autogas in Indonesia for CNG cylinders for conversion of 5,000 taxis and government vehicles to compressed natural gas (CNG). The Indonesian government is actively promoting the usage of natural gas in order to achieve their oil-to-gas program goal to reduce pollution and diversify fuel in the public transportation sector. According to new legislation that is expected to be issued by the government shortly, all gas stations will be required to have at least one dispenser of natural gas. "We are pleased

Mölnlycke opens new manufacturing plant in Havirov, Czech Republic

The opening of the new plant marks the start of Mölnlycke’s largest investment to date, EUR 67 million, and is one of the largest foreign direct investment in the country during the last years. The new plant is a milestone for the procedure tray business, and a key investment in an overall extensive global operations expansion programme by Mölnlycke. Gothenburg, Sweden – 18 May 2017  Mölnlycke, a world-leading medical products and solutions company, is pleased to announce yesterday’s opening of a new manufacturing plant in Havirov, Czech Republic. The new plant is Mölnlycke’s

A good start to the year with significant growth in the project portfolio

Summary of the first quarter 2017 · Net sales increased to 136.4 MSEK (72.9). · Operating profit went down to 21.2 MSEK (28.5). · Gross margin increased to 17.4 % (17.2). · Operating margin was 15.6 % (39.1). · Profit after tax totaled 14.4 MSEK (25.0). · Earnings per share at 0.48 SEK (0.83). · Cash flow was ‑1.5 MSEK (-87.8). · Return on equity at 18.5 % (54.2). · Debt/equity ratio was 32.2 % (31.7). · Acquisition of 530 building rights in Mariehäll and Täby. · 96.7% (98.6) sales rate for homes in production. Significant events after the balance sheet

Targovax ASA: ASCO abstract released

Oslo, Norway, 18 May 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that the abstract "A Phase I/II trial of TG01/GM-CSF and gemcitabine as adjuvant therapy for treating patients with resected RAS-mutant adenocarcinoma of the pancreas" will be presented at the American Society of Clinical Oncology Annual Meeting 2017 (ASCO). The abstract includes clinical data from the phase I/II clinical trial evaluating TG01 in resected pancreatic cancer and

SSM begins sale of 183 attractive cooperative apartments close to the city and nature in Väsjön, Sollentuna

This week, SSM will start selling 183 attractive and space-efficient cooperative apartments in the growing urban area close to nature near Väsjön in Sollentuna. The project, which is called Sollentuna Hills, comprises apartments with a balcony/French balcony or private patio. Within the framework of the project, there are also plans for modern common spaces in the form of a lush courtyard with an outdoor spa, lounge area and barbecue facilities as well as a car and bike pool with a bike workshop. Occupation is planned for 2022.SSM, Stockholm’s leading residential developer within its niche,

FMR LLC's holdings in Tikkurila fell below 9.99 percent of shares (Announcement pursuant to the Securities Markets Act, Chapter 9, Section 5)

Tikkurila OyjStock Exchange ReleaseMay 18, 2017 at 8:00 a.m. (CET+1) FMR LLC's holdings in Tikkurila fell below 9.99 percent of shares (Announcement pursuant to the Securities Markets Act, Chapter 9, Section 5) Tikkurila Oyj (business ID 0197067-4) has received a notification, based on the Securities Markets Act, from FMR LLC on May 17, 2017. The holding of the entities controlled by FMR LLC in shares of Tikkurila Oyj fell below the 1/10 (10%) threshold due to trades executed on May 16, 2017. The holding of the above mentioned entities in Tikkurila Oyj will amount to a total of

There are no items matching the current filter
There are no more items matching the current filter
Back to top